Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

Summary

Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the anticoagulant effects of edoxaban could be desirable in emergency situations. In this study, the reversal effects of haemostatic agents were determined on prothrombin time (PT) prolongation in vitro and bleeding time prolongation in vivo by edoxaban. PT using human plasma was measured in the presence of edoxaban at therapeutic and excess concentrations with the haemostatic agents, prothrombin complex concentrate (PPSB-HT), activated prothrombin complex concentrate (Feiba), and recombinant factor VIIa (rFVIIa). In rats, rFVIIa and Feiba was given during intensive anticoagulation with edoxaban. The haemostatic effect was evaluated in a model of planta template bleeding and a potential prothrombotic effect was evaluated in a venous thrombosis model. PPSB-HT, Feiba, and rFVIIa concentration-dependently shortened PT prolonged by edoxaban. Among these, rFVIIa and Feiba showed potent activities in reversing the PT prolongation by edoxaban. rFVIIa (1 and 3 mg/kg, i.v.) and Feiba (100 U/kg, i.v.) significantly reversed edoxaban (1 mg/kg/h)-induced prolongation of bleeding time in rats. In a rat venous thrombosis model, no potentiation of thrombus formation was observed when the highest dose (3 mg/kg) of rFVIIa was added to edoxaban (0.3 and 1 mg/kg/h) compared with the control. The present study indicated that rFVIIa, Feiba, and PPSB-HT have the potential to be reversal agents for edoxaban.

Keywords

Edoxaban - factor Xa inhibitor - anticoagulation - haemostatic agent - reversal

• References

• 1 Vardi M, Laor A, Bitterman H.. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes. Thromb Haemost 2009; 102: 879-886.
• 2 Holbrook AM, Pereira JA, Labiris R. et al. Systematic overview of warfarin and its drug and food interactions.. Arch Intern Med 2005; 165: 1095-1106.
• 3 Ansell J, Hirsh J, Dalen J. et al. Managing oral anticoagulant therapy. Chest 2001; 119: 22S-38S.
• 4 Thomas DP.. Does low molecular weight heparin cause less bleeding?. Thromb Haemost 1997; 78: 1422-1425.
• 5 Hettiarachchi RJ, Prins MH, Lensing AW. et al. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med 1998; 4: 220-225.
• 6 McMahan DA, Smith DM, Carey MA. et al. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13: 311-316.
• 7 Hutten BA, Lensing AW, Kraaijenhagen RA. et al. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999; 14: 303-312.
• 8 Levine MN, Raskob G, Beyth RJ. et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 287S-310S.
• 9 Levi MM, Eerenberg E, Löwenberg E. et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76.
• 10 Furugohri T, Isobe K, Honda Y. et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.. J Thromb Haemost 2008; 6: 1542-1549.
• 11 Fuji T, Wang CJ, Fujita S. et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 Trial. Pathophysiol Haemost Thromb 2010; 37: A20 (OC297).
• 12 Fujita S, Fuji T, Tachibana S. et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Pathophysiol Haemost Thromb 2010; 37: A95 (P366).
• 13 Fuji T, Fujita S, Tachibana S. et al. Efficacy and Safety of Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism Following Total Hip Arthroplasty: STARS J-V trial. Blood. 2010 116. Abstract 3320.
• 14 Weitz JI, Connolly SJ, Patel I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.. Thromb Haemost 2010; 104: 633-641.
• 15 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.. Circulation 2011; 124: 1573-1579.
• 16 Lavelle SM, Iomhair MM.. The reliability of thrombotic tendency measured by intravascular wires in the rat. Thromb Res 1997; 87: 353-357.
• 17 Bradford MM.. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
• 18 Chung N, Jeon HK, Lien LM. et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.. Thromb Haemost 2010; 105: 535-544.
• 19 Thim L, Bjoern S, Christensen M. et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-7793.
• 20 Ananyeva NM, Lee TK, Jain N. et al. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents.. Semin Thromb Haemost 2009; 35: 735-751.
• 21 Ingerslev J.. Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica 2000; 85: 15-20.
• 22 Váradi K, Negrier C, Berntorp E. et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay.. J Thromb Haemost 2003; 1: 2374-2380.
• 23 Lindley CM, Sawyer WT, Macik BG. et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-648.
• 24 Holmberg HL, Lauritzen B, Tranholm M. et al. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.. J Thromb Haemost 2009; 7: 1517-1522.
• 25 Petersen LC, Nørby PL, Branner S. et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study.. Thromb Res 2005; 116: 75-85.
• 26 Robert S, Ghiotto J, Pirotte B. et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?. Pharmacol Res 2009; 59: 160-166.
• 27 Samama MM, Kunitada S, Oursin A. et al. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. Thromb Res 2010; 126: e286-293.
• 28 Hsia CC, Chin-Yee IH, McAlister VC.. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008; 248: 61-68.
• 29 Aledort LM.. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.. J Thromb Haemost 2004; 2: 1700-1708.
• 30 Elg M, Carlsson S, Gustafsson D.. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101: 145-157.